Protocol Ledger

NCT05691244 · Phase III · RECRUITING

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Interventional Phase III clinical trial protocol NCT05691244 sponsored by Pharmazz in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-24 Enrollment: 514 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05691244
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)514 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05691244
Protocol FieldVerified Registry Value
NCT IdentifierNCT05691244
Consolidated Lead SponsorPharmazz
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment514 participants (ESTIMATED)
Registered Start Date2025-07-24
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI